An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved healing prostate cancer vaccine, Provenge, is non-poisonous and has few inconsequential effects, a altered study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy erection. "Provenge was approved based on both protection and clinical data," said guide researcher Dr Simon J Hall, easy chair of urology at Mount Sinai Medical Center in New York City.
This refuge text shows that there are very restrictive philosophy effects, Hall added. The advantage of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer faction junk than chemotherapy, which is the only other treatment option for these patients, Hall explained. In addition, Provenge has improved survival over chemotherapy, he added.
The common survival spell for men given Provenge is 4,5 months, although some patients saying their lives extended by two to three years. "This is a newly present treatment, with very restricted side effects, compared to anything else that a man would be inasmuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual meet in San Francisco.
Data from four look 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved mark of fixation and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do operate activities without any restrictions, the researchers noted.
